Ignite Creation Date:
2024-05-06 @ 6:43 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05768139
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2023-03-01
Brief Title:
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Sponsor:
Scorpion Therapeutics Inc
Organization:
Scorpion Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Solid Tumors Adult |
| Breast Cancer |
| Gynecologic Cancer |
| HNSCC |
Keywords:
| Name | View |
|---|---|
| Physiological Effects of Drugs | View |
| Breast Neoplasms | View |
| Neoplasms by Site | View |
| Neoplasms | View |
| Breast Diseases | View |
| HER2-negative breast cancer | View |
| HR-positive breast cancer | View |
| Gynecologic cancer | View |
| Endometrial cancer | View |
| Ovarian cancer | View |
| Cervical cancer | View |
| Head and neck cancer | View |
| Head and neck squamous cell carcinoma | View |
| Fulvestrant | View |
| Antineoplastic Agents | View |
| PI3Kα | View |
| PI3K alpha | View |
| PI3Kα mutation | View |
| Alpelisib | View |
| STX-478 | View |
| PI3Kα inhibitor | View |
| Estrogen Receptor Antagonists | View |
| Estrogen Antagonists | View |
| Hormone Receptor Antagonists | View |
| Hormone Antagonists | View |
| Hormones Hormone Substitutes and Hormone Antagonists | View |